Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
argenx SE
argenx SE, along with its subsidiaries is engaged in the bio-technical research on drugs and pharma processes for the treatment of oncological, autoimmune and inflammatory diseases.
IPO Date: May 18, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $34.02B
Activated in VL: True
Average Daily Range
Avg Daily Range: $3.94 | 1.53%
Avg Daily Range (30 D): $6.50 | 1.16%
Avg Daily Range (90 D): $8.20 | 1.42%
Institutional Daily Volume
Avg Daily Volume: .2M
Avg Daily Volume (30 D): .34M
Avg Daily Volume (90 D): .35M
Trade Size
Avg Trade Size (Sh.): 45
Avg Trade Size (Sh.) (30 D): 26
Avg Trade Size (Sh.) (90 D): 28
Institutional Trades
Total Inst.Trades: 1,682
Avg Inst. Trade: $9.27M
Avg Inst. Trade (30 D): $14.53M
Avg Inst. Trade (90 D): $15.89M
Avg Inst. Trade Volume: .02M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $8.94M
Avg Closing Trade (30 D): $10.09M
Avg Closing Trade (90 D): $11.23M
Avg Closing Volume: 21.29K
   
News
Jul 16, 2025 @ 4:30 AM
[Latest] Global Ultomiris Drug Market Size/Share W...
Source: Custom Market Insights
Jun 30, 2025 @ 5:00 AM
argenx Advances Clinical Development of ARGX-119 i...
Source: Argenx Se
Jun 20, 2025 @ 5:00 PM
argenx Announces European Commission Approval of V...
Source: N/A
Apr 10, 2025 @ 9:47 PM
argenx Announces FDA Approval of VYVGART Hytrulo P...
Source: N/A
Apr 8, 2025 @ 6:17 PM
Argenx's Flagship Drug Vyvgart Shows Sustained Dis...
Source: Vandana Singh